Levigress Syrup contains Levetiracetam 100 mg as its active ingredient and is indicated for the adjunctive treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam is an antiepileptic drug that modulates synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Levigress Syrup offers a convenient oral liquid formulation suitable for pediatric and adult patients who have difficulty swallowing tablets. The syrup is rapidly absorbed, with peak plasma concentrations typically reached within one hour post-administration, and it exhibits linear pharmacokinetics with minimal protein binding. Dosage should be individualized based on clinical response and tolerability, with careful titration recommended to minimize adverse effects such as somnolence, dizziness, and behavioral symptoms. Levigress Syrup is primarily eliminated unchanged via renal excretion; thus, dose adjustments are necessary in patients with impaired renal function. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Caution is advised when used concomitantly with other central nervous system depressants. Regular monitoring and adherence to prescribed dosing enhance therapeutic outcomes and patient safety.